Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 22, 2025 16:05 ET | Source: NurExone Biologic Inc

NurExone Appoints Biotech Industry Leader - Jacob Licht to Lead U.S. Operations and Exo-Top Manufacturing Expansion and Completes Continuance into Ontario

TORONTO and HAIFA, Israel, April 22, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a preclinical-stage biotechnology company...
February 14, 2025 16:03 ET | Source: NurExone Biologic Inc

NurExone Biologic Continues Expansion of U.S. Presence and Awareness with Prestigious Conference Presentation

TORONTO and HAIFA, Israel, Feb. 14, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (Germany: J90) (“NurExone” or the “Company”) is excited to announce that it will be...
February 05, 2025 16:04 ET | Source: NurExone Biologic Inc

NurExone Forms Exo-Top Inc. in the U.S. for Exosome Manufacture and Commercialization

NurExone Biologic Inc. announces formation of a U.S.-based subsidiary, Exo-Top Inc. for fully characterized GMP Exosome production.
January 08, 2025 16:12 ET | Source: NurExone Biologic Inc

NurExone Biologic Secures Master Cell Bank

NurExone Biologic Secures Master Cell Bank - a Key Milestone for Therapeutic Exosome Production
August 15, 2024 16:03 ET | Source: NurExone Biologic Inc

NurExone Biologic Achieves Key Milestone in Support of Robust Exosome Manufacturing Process

NurExone’s reliable production from diverse biological sources allows NurExone to optimize exosome production with consistency and efficiency
February 20, 2024 16:05 ET | Source: NurExone Biologic Inc

NurExone’s Intellectual Property Portfolio Expands

NurExone's Intellectual Property portfolio is expanding to encompass processes and compositions related to exosomes in large-scale production